NCT00468897View on ClinicalTrials.gov

A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 21, 2007

Primary Completion Date

May 2, 2007

Study Completion Date

May 2, 2007

Conditions

Alzheimer's Disease

Interventions

DRUG

RSG XR

RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.

Trial Locations (1)

41460

GSK Investigational Site, Neuss